Literature DB >> 17290185

Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease.

Yasushi Takagi1, Ken-Ichiro Kikuta, Kazuhiko Nozaki, Motoaki Fujimoto, Junya Hayashi, Hirotoshi Imamura, Nobuo Hashimoto.   

Abstract

OBJECTIVE: Moyamoya disease (MMD) is a cerebrovascular occlusive disease characterized by progressive stenosis or occlusion at the distal ends of the bilateral internal arteries. In MMD, intimal hyperplasia was previously reported to be found in autopsy samples. In this study focusing on the mechanism of remodeling of the intracranial arterial walls of patients with MMD, we surgically collected tiny pieces of the wall of the middle cerebral artery (MCA) from patients with MMD and analyzed them using histological and immunohistochemical methods.
METHODS: Twelve patients underwent surgical procedures for treatment of standard indications of MMD at Kyoto University Hospital. Specimens of MCA were obtained from MMD patients during the surgical procedures. Nine MCA samples were also obtained in the same way from control patients. The samples were analyzed by immunohistochemical methods.
RESULTS: MCA specimens from MMD patients had a thicker intima than those from the control group. In MMD samples, the immunoreactivity indicating hypoxia-inducing factor-1alpha was higher in the endothelium and intima; endoglin expression was also higher in the endothelium. No vascular endothelial growth factor immunoreactivity was detectable in the MMD samples. In addition, transforming growth factor-beta3 immunoreactivity was also detected and was co-localized with that of hypoxia-inducing factor-1alpha and endoglin, mainly in the endothelium.
CONCLUSION: Our results indicate that the MCA specimens from MMD patients had thicker intimal walls than the specimens from control patients. In addition, hypoxia-inducing factor-1alpha and endoglin were overexpressed in the intima of the MCA of MMD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290185     DOI: 10.1227/01.NEU.0000249275.87310.FF

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  21 in total

1.  A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians.

Authors:  Wanyang Liu; Hirokuni Hashikata; Kayoko Inoue; Norio Matsuura; Yohei Mineharu; Hatasu Kobayashi; Ken-Ichiro Kikuta; Yasushi Takagi; Toshiaki Hitomi; Boris Krischek; Li-Ping Zou; Fang Fang; Roman Herzig; Jeong-Eun Kim; Hyun-Seung Kang; Chang-Wan Oh; David-Alexandre Tregouet; Nobuo Hashimoto; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2009-11-19       Impact factor: 3.674

2.  Common genetic polymorphisms in moyamoya and atherosclerotic disease in Europeans.

Authors:  Constantin Roder; Vera Peters; Hidetoshi Kasuya; Tsutomu Nishizawa; Yayoi Takehara; Daniela Berg; Claudia Schulte; Nadia Khan; Marcos Tatagiba; Boris Krischek
Journal:  Childs Nerv Syst       Date:  2010-08-06       Impact factor: 1.475

Review 3.  Current Clinical Applications of Intracranial Vessel Wall MR Imaging.

Authors:  Raghav R Mattay; Jose F Saucedo; Vance T Lehman; Jiayu Xiao; Emmanuel C Obusez; Scott B Raymond; Zhaoyang Fan; Jae W Song
Journal:  Semin Ultrasound CT MR       Date:  2021-08-01       Impact factor: 1.641

4.  Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS.

Authors:  Yoshio Araki; Kazuhiro Yoshikawa; Sho Okamoto; Masaki Sumitomo; Mikio Maruwaka; Toshihiko Wakabayashi
Journal:  BMC Neurol       Date:  2010-11-08       Impact factor: 2.474

5.  Advanced intimal hyperplasia without luminal narrowing of leptomeningeal arteries in CADASIL.

Authors:  Hairong Dong; Haixia Ding; Kelly Young; Mila Blaivas; Paul J Christensen; Michael M Wang
Journal:  Stroke       Date:  2013-03-12       Impact factor: 7.914

6.  Significance of cyclooxygenase-2 elevation in middle cerebral artery for patients with hemorrhagic moyamoya disease.

Authors:  Jian-Jian Zhang; Zhong-Wei Xiong; Sheng Wang; Shou-Jia Sun; Hao Wang; Xiao-Lin Wu; Long Wang; Hua-Qiu Zhang; Chao You; Yu Wang; Jin-Cao Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-04-13

7.  Generation of human vascularized brain organoids.

Authors:  Missy T Pham; Kari M Pollock; Melanie D Rose; Whitney A Cary; Heather R Stewart; Ping Zhou; Jan A Nolta; Ben Waldau
Journal:  Neuroreport       Date:  2018-05-02       Impact factor: 1.837

Review 8.  Pathological Circulating Factors in Moyamoya Disease.

Authors:  Yao-Ching Fang; Ling-Fei Wei; Chaur-Jong Hu; Yong-Kwang Tu
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

9.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.

Authors:  Wanyang Liu; Daisuke Morito; Seiji Takashima; Yohei Mineharu; Hatasu Kobayashi; Toshiaki Hitomi; Hirokuni Hashikata; Norio Matsuura; Satoru Yamazaki; Atsushi Toyoda; Ken-ichiro Kikuta; Yasushi Takagi; Kouji H Harada; Asao Fujiyama; Roman Herzig; Boris Krischek; Liping Zou; Jeong Eun Kim; Masafumi Kitakaze; Susumu Miyamoto; Kazuhiro Nagata; Nobuo Hashimoto; Akio Koizumi
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

10.  Is there a role for treating inflammation in moyamoya disease?: a review of histopathology, genetics, and signaling cascades.

Authors:  Adam M H Young; Surya K Karri; Christopher S Ogilvy; Ninghui Zhao
Journal:  Front Neurol       Date:  2013-08-14       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.